The study’s main goal was to figure out how HDACs play a role in the pathophysiology of Diabetic Nephropathy and whether targeting certain HDACs could help halt the progression of the disease. Benefits and downsides of HDAC inhibitors, as well as potential challenges In Diabetic Nephropathy, HDAC inhibitors have various advantages: TGF-beta 1 decreased, Collagen I decreased, Fibronectin decreased-SMA decreased-cadherin decreased, TGF-beta 1 decreased, Collagen I decreased, Fibronectin decreased-SMA decreased, TGF-beta 1 decreased, TGF-beta 1 decreased, TGF-beta 1 decreased, TGF-beta 1 decreased, TGF- Reduces the effects of eNOS, iNOS, and TGF-1 on fibrogenesis, apoptosis, and DNA damage. Klotho is preserved. Inhibits the Wnt signalling pathway. EGFR pathway inactivation Insulin sensitivity is improved. Insulin resistance and Beta cell proliferation are reduced. Apoptosis is reduced. Nephrin and podocin are restored. Inflammatory protein is suppressed. Insulin secretion increased, and glucose control improved. By activating Nrf2, it prevents endothelial impairment caused by diabetes. Prevents lipid dysfunction in the liver. Reduce the risk of diabetic retinopathy, In diabetics, it improves heart metabolic function. Obesity and body weight should be reduced. It slows down the ageing process. It helps to keep atherosclerosis at bay. Autophagy in the heart is prevented. TNF, MMP, ER stress, and caspase activation are all decreased when the ER Stress pathway is inhibited. The sole disadvantage is that several HDAC inhibitors are said to produce too much ROS. However, this is countered by klotho, which may be triggered by inhibiting HDAC specifically, reducing oxidative stress.

Author (S) Details

Navneet Soni
Bharati Vidyapeeth Deemed University Medical College and Hospital, India.

View Book :- https://stm.bookpi.org/NFMMR-V13/article/view/3537